Document is current
Any future updates will be listed below
-
Authors
Moretto, Roberto https://orcid.org/0000-0001-8456-9269
Elliott, Andrew
Rossini, Daniele
Intini, Rossana
Conca, Veronica https://orcid.org/0000-0001-7713-4005
Pietrantonio, Filippo https://orcid.org/0000-0002-8530-8420
Sartore-Bianchi, Andrea https://orcid.org/0000-0003-0780-0409
Antoniotti, Carlotta
Rasola, Cosimo
Scartozzi, Mario
Salati, Massimiliano
Pella, Nicoletta
Calegari, Maria Alessandra
Carullo, Martina
Corti, Francesca
Mauri, Gianluca
Fassan, Matteo https://orcid.org/0000-0001-6515-5482
Masi, Gianluca
Brodskiy, Pavel
Lenz, Heinz-Josef https://orcid.org/0000-0003-2178-9568
Shields, Anthony
Lonardi, Sara https://orcid.org/0000-0002-7593-8138
Korn, Michael
Cremolini, Chiara https://orcid.org/0000-0002-0520-4841
- License Information
-
More Information
Article History
Received: 4 January 2022
Revised: 2 April 2022
Accepted: 9 May 2022
First Online: 3 June 2022
Competing interests
: AE: Employee of Caris Life Sciences. PB: Employee of Caris Life Sciences. FP: honoraria for speaker activities and participation in advisory boards from Sanofi, Amgen, Bayer, Merck-Serono, Lilly, Astrazeneca, Servier, Organon, MSD; and research grants from BMS and Astrazeneca. AS-B: Honoraria: Amgen, Bayer, MSD, Servier. Consulting or advisory role—Amgen, Bayer, Novartis, Sanofi, Servier. MS: Advisory board, speakers’ bureau MERCK, MSD, Sanofi, Amgen, BMS, EISAI, Servier. GM: Honraria—Amgen, F. HoffmaneLa Roche, Bayer, Merk Serono, Sirtex. SL: Speakers’ Bureau—Amgen, Merck, Roche, Lilly, Bristol-Myers Squibb, Pierre-Fabre, GSK and Servier. Consulting or advisory role—Amgen, MSD, Merck Serono, Lilly, Astra Zeneca, Incyte, Daiichi-Sankyo, Bristol-Myers Squibb, Servier, Research funding to Institution—Bayer, Merck, Amgen, Roche, Lilly, Astra Zeneca Bristol-Myers Squibb. WMK: Consultant—Merck. Employee of Caris Life Sciences. CC: honoraria—Amgen, Bayer, Merck, Roche and Servier. Consulting or advisory role—Amgen, Bayer, MSD, Roche. Speakers’ Bureau—Servier. Research funding—Bayer, Merck, Servier. Travel, accommodations and expenses—Roche and Servier. The remaining authors declare no competing interests.
: BRAF BeCool study was conducted in accordance with the Declaration of Helsinki. Approval for BRAF BeCool protocol was obtained from local ethics committees of participating sites.
: Not applicable.
